

News Release

Philadelphia, PA USA March 10, 2015

Leading medical research centers engage Lyophilization Technology in recent collaborations for accelerated development and clinical trial material.

Medical research and product development play a vital role in translating discoveries into new products for advancing the course of therapies, with improved treatment outcomes and patient care. Lyophilization Technology's (LTI) participation in achieving these goals in the development of lyophilized products is through ongoing collaborations with virtual, small, mid-size and large multinational biopharmaceutical companies, as well as innovators within the medical research community.

Four prominent medical research centers have recently engaged LTI for product development, followed by preparing material to start clinical studies. Supporting important medical advances through collaborating with these medical research groups is crucial for bringing new therapies for improved courses of treatment, with greater success for patient outcomes.

Enlisted by a leading neuroscience research institute in the Mid-Atlantic region, LTI urgently prepared clinical material for a life-saving course of treatment. The FDA approved the lyophilized product for administration to a limited number of patients under a compassionate IND. With quick action and intense focus, and only milligrams of drug substance available, LTI was able to supply the critical clinical material for the defined patient population with an expedited delivery. Follow-on studies to an expanded population of patients are scheduled for the second half of this year.

A prominent cancer center research institute in the northeastern metropolitan area selected LTI to aid in the development and production of clinical material for an oncolytic with great promise. This "first in class" therapeutic has shown to be well tolerated at high doses with the potential of being effective in multiple indications. With clinical studies started earlier in 2014, resupply for expanded clinical studies was provided in the fourth quarter. Great interest in additional indications is leading to further development of specific product presentations to support expanded clinical studies and is ongoing.

LTI is supporting a highly respected medical center in the New England area in providing clinical material as a prophylactic therapy for prevention of cardio-vascular events during surgical procedures. This first in class new drug entity possesses unique biochemical properties that requires special handling during manufacturing.

Innovators at a major southern medical institute sought LTI for product development and preparation of clinical material to start safety studies of a new antibiotic for infections resistant to existing therapies. This was followed by development of a

presentation for dosing efficacy studies that began early in 2015. Further development is being led by a pharmaceutical development organization in Europe for multinational clinical studies, with continued material supply provided by LTI.

Collaborating with many leading medical research institutions, the group at LTI focuses on building lasting relationships where clients are able to leverage on our expertise and resources to facilitate successful project outcomes. The expertise, flexibility, and ability to design and develop a product to produce clinical material allows for moving product from discovery to the bedside quickly. LTI's President, Ed Trappler, summarizes, "Our aspiration is the successful application and technological development of new lyophilized products for treatment of critical, often life threatening conditions. Our goal is to support our clients in the development of lyophilized products that improve the quality of life." These projects lead to the mutual benefit of our clients as well as patients in need. The vision at LTI remains: Provide scientific services and technical support to our clients for development of health care products, spanning virtual companies to large multinational corporations, including very brilliant researchers at medical institutions.

About Lyophilization Technology: Lyophilization Technology provides scientific services and technical support in freezing and freeze drying for the health care industries involved in producing pharmaceuticals, biologics, diagnostics, biopharmaceuticals, and medical devices. Since its founding in 1992, the company has grown to provide a wide variety of services in diverse applications of the technology. Scientific services consist of development, clinical material preparation, optimization and troubleshooting lyophilized products and processing. Services provided to the industry also include transferring newly developed and currently marketed products to multiple manufacturing sites, streamlining operations, and improving quality and regulatory compliance. Learn more and contact LTI at www.lyotechnology.com for further information.